Stock Data
$1.01 (2.08%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
DRUG MANUFACTURERS - SPECIALTY & GENERIC
Alkermes plc is a biopharmaceutical company based in Dublin, Ireland, focusing on developing treatments for critical unmet medical needs. It specializes in creating innovative therapies for alcohol and opioid dependence, schizophrenia, bipolar I disorder, and other neurological disorders. Its product lineup includes ARISTADA and VIVITROL, among others, aimed at improving patient outcomes. Alkermes also collaborates with leading pharmaceutical companies and leverages proprietary technology platforms to advance its research and development efforts, making significant contributions to the field of medicine since its establishment in 1987.
Alkermes blew past revenue expectations as the Avadel acquisition kicked in with LUMRYZ contributing $96.6 million, but earnings cratered to zero on acquisition charges and $26.4 million in contingent consideration step-ups. The company also announced CEO Richard Pops is handing the reins to Blair Jackson effective August 1.
94 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
